Novo Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Lilly’s Mounjaro

Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro

COPENHAGEN, Sept 29 (Reuters) - Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an ​escalated dose of its diabetes drug, Ozempic, ‌had a lower risk of major cardiovascular events compared to those who swi...

Novo Nordisk: Ozempic 2mg Linked to Lower Cardiovascular Event Risk vs Eli Lilly's Mounjaro Study

COPENHAGEN: Novo Nordisk said on Tuesday ‌a ​real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's Mounjaro.The company said patients who escalated their dose of Ozempic to 2 milligrams (mg) from 1 mg saw a statistically significant 6% lower risk of major adverse cardiovascular events compared …

Novo: Ozempic cuts heart risks better than Mounjaro

Novo Nordisk A/S, doing business as Novo, announced on Tuesday a study showing that its diabetes and obesity drug Ozempic is associated with a lower risk of major adverse cardiovascular events in adul...